Global Anatomic Pathology Testing Market Size to Reach USD 11.57 Billion by 2021: Technavio

Technavio has published a new report on the global anatomic pathology testing market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--According to the latest market study released by Technavio, the global anatomic pathology testing market size is projected to grow to USD 11.57 billion by 2021, at a CAGR of more than 8% over the forecast period.

This research report titled ‘Global Anatomic Pathology Testing Market 2017-2021’ provides an in-depth analysis of the market in terms of products (instruments and imaging systems; and consumables and accessories), application (breast cancer, lung cancer, colorectal cancer, lymphoma, cervical cancer, and prostate cancer), end-user (hospitals and physicians’ office laboratories), and geography (the Americas, EMEA, and APAC).

The anatomic pathology testing helps in identifying abnormalities in tissue or cell lines and develops personalized care treatment. The Americas is expected to generate the highest revenue and maximum incremental growth in the anatomic pathology testing market over the forecast period, driven by the increased funding to research institutes for studying personalized medicines.

Request a sample report: http://www.technavio.com/request-a-sample?report=56860

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Technavio analysts highlight the following three factors that are contributing to the growth of the global anatomic pathology testing market:

  • Use of biomarkers for disease diagnostics and increasing efficiency
  • Growing prevalence of cancer in demographics
  • Paradigm shift toward precision diagnostics through personalized medicine

Use of biomarkers for disease diagnostics and increasing efficiency

Genomic biomarkers are used to evaluate pharmacological, physiological, and disease processes required for various clinical studies in proteomics, genomics, transcriptomics, metabolomics, and microbiology labs. Biomarkers such as keratins, vimentin, S100protein, CD45, CD3, CD20, and CD30 are popularly used for cancer diagnostics in lab tests.

The analysis of these biomarkers in lab tests aid in disease prognosis, elucidation of related pathways, and identifying possible treatments. The rise in the volume of biomarker analysis for various disease diagnosis processes will lead to the use and sales of tissue diagnostic products,” says Srinivas Sashidhar, a lead analyst at Technavio for in-vitro diagnostics research.

Growing prevalence of cancer in demographics

People aged above 60 are more susceptible to chronic diseases such as cancer and cardiovascular diseases. Currently, the number of individuals in the said age group are higher than at any other point in history, resulting in increasing demand for the effective screening tools for these diseases. The early diagnosis and constant monitoring of individuals are essential to identify, treat, and manage the spread of these diseases. Vendors in the market are responding to this demand by introducing tissue diagnostic products, including instruments, testing kits, and reagents. Also, several governments are undertaking early diagnosis programs, which is directly impacting market growth.

Paradigm shift toward precision diagnostics through personalized medicine

Personalized medicine is tailor-made for the individual under treatment based on their pathology and physiology, resulting in enhanced healthcare. Anatomic pathology tests are carried out to understand the individual’s cellular framework, aiding in the development of personalized treatment,” explains Srinivas.

Personalized medicine is prepared based on the study of the defective proteins and genes extracted from tissues identified during the pathology tests. Currently, these medicines are in high demand, as it involves better patient management and enables individualized treatment through diagnostic tests for real-time and rapid results.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Abbott Diagnostics
  • Agilent Technologies
  • Danaher
  • Roche Diagnostics
  • Thermo Fisher Scientific

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, medical imaging, and patient monitoring devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

According to the latest market study released by Technavio, the global anatomic pathology testing market size is projected to grow to USD 11.57 billion by 2021, at a CAGR of more than 8%.

$Cashtags

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com